You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Rational Design of Live Attenuated Influenza A Vaccine Candidates

    SBC: Codagenix Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Despite the availability of influenza vaccines, approximately 35,000 individuals die each year in the US alone from influenza, and influenza-related complications. The clinical impact of Influenza motivates the search for new, more effective vaccines that can be rapidly designed and easily produced. We have developed a rational, computer-aided approach to const ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Suv39H Targeted Therapy for Treatment of Childhood Rhabdomyosarcoma

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Rhabdomyosarcoma (RMS) is a childhood malignant tumor and is thought to arise due to the arrest of skeletal muscle differentiation (myogenesis) program. It accounts for 3.5% of all malignancies in children. Despite multimodality therapeutic treatment approaches, the outlook for patients with metastatic subtype, alveolar rhabdomyosarcoma (ARMS), remains unchange ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Testing of novel anti-cancer compounds Curaxins against pancreatic cancer

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Mortality from pancreatic ductal adenocarcinoma (PDA) is close to 100% due to the absence of effective treatment approaches. This proposal is focused on determining the therapeutic potential of a new class of candidateanti-cancer agents named Curaxins (CXs) for treatment of PDA. The rationale for this is based on our discovery that CXs inhibit the activity of ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Diagnosis, Prognosis and Treatment of hRgr associated Hematopoietic Malignancies

    SBC: OMNICYTE            Topic: NCI

    DESCRIPTION (provided by applicant): OmniCyte is dedicated to the development of novel targeted treatments for T-Cell malignancies. The company will pursue the development of a commercial diagnostic specifically targeted at a subgroup of T- cell malignancies, including Acute Lymphoblastic Leukemia (ALL). Because T-cell lymphomas and leukemias generally make up the minority of each type of lymphoma ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Calibrated Methods for Quantitative PET/CT Imaging

    SBC: Kitware, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The overall goal of this STTR project is to develop calibrated 3D quantitative analysis tools that directly support improved quantitative accuracy in clinical trials using PET/CT imaging. Pocket phantom technology willbe extended to characterize, perform quality assurance, and improve measurement of PET/CT scans on a per-patient scan basis. We will extend a 2nd ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Devices enabling improved light delivery for photodynamic therapy of oral cancer

    SBC: LUCIFICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Oral cancer is a devastating disease that impacts 640,000 people worldwide. Though treatment with photodynamic therapy can be effective with significantly less morbidity than alternative therapies, problems arising fromless than optimal light delivery to the oral cavity have hindered its widespread application. The goal of the proposed research is to provide a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors

    SBC: ARISAPH PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): In the United States colorectal cancer (CRC) is the third leading cause of cancer mortality. Surgery is the primary treatment for early stage CRC; but adjuvant therapy is usually needed in advanced disease. Approximately 55% of CRC patients have metastatic disease for which the prognosis is poor despite incremental improvements due to introduction of irinotecan ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluation of In Vitro Companion Diagnostic Monoclonal Antibodies for Use in a St

    SBC: INTICA BIOMEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This project is designed to allow independent experts in the development and/or application of in vitro breast cancer diagnostic tests, Drs. Badve (breast pathologist) and Sledge (breast oncologist), to evaluate INTICA's candidate anti-DEspR mAbs to develop the preliminary materials and methods for a commercially viable companion diagnostic test. DEspR, th ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. A new class of biodegradable synthetic biomaterial for seroma prevention

    SBC: IFYBER, LLC            Topic: NIBIB

    DESCRIPTION (provided by applicant): Seromas are a common post-operative complication particularly prevalent following ablative and reconstructive surgeries. Without timely intervention post-operative seromas can lead to significant patient morbidity including infection, tissue necrosis, permanent cystic cavities, reduced limb mobility and permanent disfigurement. The high incidence of seroma form ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government